Key facts
- Status: Acquired/Merged (Operating Subsidiary).
- ·Watchlist + deal alerts for AllIn Bio
- ·The full record, as it builds
Funding rounds
No funding rounds for AllIn Bio are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About AllIn Bio
Provider of immunology services intended to transform the treatment of chronic inflammatory diseases. The company offers a targeted approach to identifying and treating genetically predisposed patients early, enabling healthcare providers to intervene sooner and improve long-term disease management and outcomes.
- Sector
- Healthcare
- HQ
- Woodside, CA, United States
- Founded
- 2024
- Website
- allinbio.com/
- Ownership
- Acquired/Merged (Operating Subsidiary)
AllIn Bio doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in AllIn Bio shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on AllIn Bio in its N-PORT filings yet. We sweep new filings monthly.